Literature DB >> 2176276

Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol.

M Perez-Reyes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2176276

Source DB:  PubMed          Journal:  NIDA Res Monogr        ISSN： 1046-9516


× No keyword cloud information.
  11 in total

1.  Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration.

Authors:  Garry Milman; Allan J Barnes; David M Schwope; Eugene W Schwilke; William D Darwin; Robert S Goodwin; Deanna L Kelly; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-06-08       Impact factor: 8.327

Review 2.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

3.  Validation of an enzyme immunoassay for detection and semiquantification of cannabinoids in oral fluid.

Authors:  David M Schwope; Garry Milman; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-04-01       Impact factor: 8.327

4.  Oral fluid cannabinoid concentrations following controlled smoked cannabis in chronic frequent and occasional smokers.

Authors:  Sebastien Anizan; Garry Milman; Nathalie Desrosiers; Allan J Barnes; David A Gorelick; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-08-17       Impact factor: 4.142

5.  Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects.

Authors:  Edward J Cone; George E Bigelow; Evan S Herrmann; John M Mitchell; Charles LoDico; Ronald Flegel; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2015-07-02       Impact factor: 3.367

Review 6.  A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.

Authors:  Emily J Cox; Neha Maharao; Gabriela Patilea-Vrana; Jashvant D Unadkat; Allan E Rettie; Jeannine S McCune; Mary F Paine
Journal:  Pharmacol Ther       Date:  2019-05-07       Impact factor: 12.310

7.  Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration.

Authors:  Garry Milman; David M Schwope; Eugene W Schwilke; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis
Journal:  Clin Chem       Date:  2011-08-29       Impact factor: 8.327

Review 8.  Cannabinoid-based medicines for neurological disorders--clinical evidence.

Authors:  Stephen Wright
Journal:  Mol Neurobiol       Date:  2007-06-29       Impact factor: 5.590

9.  Acute subjective effects after smoking joints containing up to 69 mg Δ9-tetrahydrocannabinol in recreational users: a randomized, crossover clinical trial.

Authors:  Claudine C Hunault; Koen B E Böcker; R K Stellato; J Leon Kenemans; Irma de Vries; Jan Meulenbelt
Journal:  Psychopharmacology (Berl)       Date:  2014-05-31       Impact factor: 4.530

10.  A Preliminary Investigation of Individual Differences in Subjective Responses to D-Amphetamine, Alcohol, and Delta-9-Tetrahydrocannabinol Using a Within-Subjects Randomized Trial.

Authors:  Margaret C Wardle; Benjamin A Marcus; Harriet de Wit
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.